Rituximab NCT05332587 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 16 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 3

Clinical phase

Unknown status

Recruitment status

not reported

Planned enrollment

2022-07-01

Primary-completion proxy

Executive view

NCT05332587 evaluates Rituximab in Myasthenia Gravis. The disclosed sponsor is the First Affiliated Hospital of Sun Yat-Sen University, the design is Interventional, and the geographic footprint is China. The first listed primary endpoint is Time to reach MM-1, the proportion of drug remission., assessed over 27 weeks.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT05332587 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Myasthenia Gravis landscape. Drug & Asset MCP drug_fetch was queried for Rituximab, while Company & Deal Intelligence MCP organization_fetch was queried for the First Affiliated Hospital of Sun Yat-Sen University.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT05332587	Rituximab	Phase 3 / Unknown status	the First Affiliated Hospital of Sun Yat-Sen University	China	Time to reach MM-1, the proportion of drug remission. 27 weeks	2022-07-01
NCT05403541	Batoclimab	Phase 3 / Terminated	Immunovant Sciences Ltd.	Argentina, Romania, Hungary, United States, Japan, United Kingdom, Spain, Canada, South Korea, Poland, Brazil, Mexico, Italy, Serbia, Germany	Change from Baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) score in acetylcholine receptor (AChR) Ab… Baseline (Day 1) to Week 12	2025-01-10
NCT05332210	Batoclimab	Phase 3 / Completed	Hopp Pharmaceutical (Guangzhou) Co., Ltd.	China	Incidence of AEs during the study during the study，up to 24 weeks	2024-04-26
NCT05265273	Nipocalimab-aahu	Phase 2/3 / Recruiting	Janssen Research & Development LLC	Netherlands, United States, Japan, Poland	Change from Baseline in Total Serum Immunoglobulin-G (IgG) Levels Up to 3 years	2027-06-30
NCT05218096	Vemircopan	Phase 2 / Terminated	Alexion Pharmaceuticals, Inc.	Canada, United States, Taiwan Province, South Korea, Italy, Serbia, Germany, Spain	Percentage Of Participants With a Myasthenia Gravis Activities of Daily Living (MG-ADL) Total Score Reduction Of ≥ 2 Po… Baseline through Week 8	2023-11-30

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT05332587 is a Phase 3, unknown status study with not reported planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.

The primary endpoint is “Time to reach MM-1, the proportion of drug remission.” over “27 weeks.” The retrieved endpoint description is: Mild clinical Manifestations（MM-1）was the primary efficacy endpoint observed. Record the time the patient appears from the time of medication to the time of MM-1，and calculate the percentage of Pharmacologic Remission (PR). Criteria for PR: The patient has had no symptoms or signs of MG and continues to take some form of therapy for MG. There is no weakness of any muscle on careful examination by someone skilled in the evaluation of neuromuscular disease. Isolated weakness of eyelid closure is accepted. Patients taking cholinesterase inhibitors are excluded from this category because their use suggests the prese….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Myasthenia Gravis. These records do not establish direct evidence for NCT05332587 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Rituximab is indexed as Monoclonal antibody with CD20 biology and a global stage of Approved. The asset profile lists Genentech, Inc. as an originator or developer.

the First Affiliated Hospital of Sun Yat-Sen University is indexed in an unreported country with the website https://www.fahsysu.org.cn. Provides health care and medical education services The record lists 15 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Rituximab is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT05332587
Protocol source: https://clinicaltrials.gov/study/NCT05332587
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 October 2026.

Rituximab in Myasthenia Gravis is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Time to reach MM-1, the proportion of drug remission. and 2022-07-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP